Global Ophthalmic Drugs Market Landscape: Trends and Market Share to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Ophthalmic Drugs Industry?
The market size for outsourcing cancer immunotherapy drug discovery has seen a surge in recent years. It is projected to increase from $1.5 billion in 2024 to $1.66 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. The growth witnessed in the past is due to factors such as an uptick in adverse drug reaction cases, a rising demand for comprehensive genomic testing, an escalating global occurrence of cancer, an increased need for targeted therapy, and an upswing in the number of clinical trials.
The market size for cancer immunotherapy drug discovery outsourcing is poised for substantial expansion in the coming years. It is projected to reach “$2.45 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.2%. The surge during this forecast period can be credited to the growing significance of personalized medicine, escalating number of diagnostic examinations, more concentrated efforts on unique cancer treatments, heightened healthcare spending, and a surge in both cancer occurrences and awareness. The forecast period will also see key trends such as advancement in diagnostic techniques, the next phase of sequencing (NGS), the adoption of artificial intelligence (AI), liquid biopsy technology, the advent of point-of-care companion diagnostic tools, and ground-breaking testing technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp
#Which Factors Are Currently Driving The Growth Of The Ophthalmic Drugs Market?
The heightened occurrence of ophthalmic conditions is anticipated to fuel the expansion of the ophthalmic drug market. Ophthalmic disorders encompass any disease or condition that impacts the eye and its adjunct structures, leading to vision impairment and various eye diseases. Ophthalmic pharmaceuticals are medicinal products utilized for the treatment of these eye conditions. Therefore, the rising prevalence of these disorders amplifies the need for ophthalmic drugs. For instance, the Centers for Disease Control and Prevention (CDC), a US-based government entity, projected that in 2022, 17.2% of Americans aged over 40 – approximately 20.5 million individuals – would be affected by cataracts in at least one eye. Hence, the burgeoning frequency of such ophthalmic disorders is catalyzing the ophthalmic drug market.
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas
Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy
What Upcoming Trends Are Expected To Impact The Ophthalmic Drugs Market Globally?
Prominent businesses in the cancer immunotherapy drug discovery outsourcing market are leveraging strategic alliances to bolster the manufacture of cancer drugs and secure a competitive edge. A strategic partnership generally entails a cooperative bond between multiple organizations, as they merge their assets, capabilities, and endeavors to attain mutual goals or targets. For instance, in February 2022, an outsourcing contract was debuted by Ono Pharmaceutical Co., Ltd., a pharmaceutical entity based in Japan, and Bristol-Myers Squibb, a biopharmaceutical entity based in the US, with Prime Research Institute for Medical Research, Inc, a research establishment in Japan. The collaborative project in focus manipulates a clinical research study on gastric cancer patients undergoing treatment with Opdivo (nivolumab) in concurrence with chemotherapy. This industry-driven initiative features a substantial, multi-entity study that employs PRiME-R’s data input support mechanism known as CyberOncology. This system enables standardization, organization, regulation, and amalgamation of real-time data in cancer clinical routine. This clinical investigation, which leverages CyberOncology, assesses Opdivo in conjunction with chemotherapy for untreated advanced or repeat gastric cancer. It engages around 30 medical institutions nationwide and aims to expedite data input, augment data precision, and speed up analysis.
Who Are The Main Participants Shaping The Ophthalmic Drugs Market Landscape?
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc., ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation
Which Region Currently Holds The Largest Share In The Ophthalmic Drugs Market?
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
